The aim of this study was to discover the clinical value of the tumour marker AMDL DR-70 in a group of patients with cancer of the tongue. Serum concentrations of AMDL DR-70 were estimated by enzyme linked immuno-sorbent assay in 52 patients with carcinoma of the tongue and compared with 40 controls and 42 patients with benign lesions in the tongue. Thirty-nine patients with carcinoma of the tongue had results above 6 mg/L (75%), compared with 3/40 (7%) in healthy controls and 4/42 (10%) in those with benign tumours. The concentration of AMDL DR-70 in serum correlated significantly with 3-year survival.
From the above, you can calculate the sensitivity and specificity.
Senstivity = 39 / 52 = 75%
Specificity for those having tumors 83%
for general screening, you would have 10% of all healthy people testing positive. That would be a HUGE number considering the incidence of cancer in the tounge is very low.
I have never shorted nor intend to have any financial interest in this stock. I am not connected with anyone who trades, shorts or has financial interests in this stock. I only post facts and my opinions. I do not post on IHUB with different aliases.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.